Stemline Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Stemline Therapeutics Inc (STML) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Stemline Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 47M vs 9M combined for tracked competitors (83.3% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-24.6% annualized vs trailing 12 months), vs decelerating (-82.4%) for its tracked peer group.
- Growth: Stemline Therapeutics Inc generated 75.7% revenue growth year over year in Q1 2020, vs 15.3% for its tracked competitors combined.
- Profitability: Its -240.0% net margin compares with -2,014.0% for the peer group.
- Peer revenue share: Stemline Therapeutics Inc accounted for 95.5% of combined revenue among its tracked peer group, up from 93.3% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
STML Sales vs. its Competitors, Q1 2020
Stemline Therapeutics Inc reported revenue growth of 75.74 % year on year in Q1 2020, above its competitors' combined revenue growth of 15.28 %.
With a net margin of -239.99 %, Stemline Therapeutics Inc achieved higher profitability than its competitors (-2,013.98 %).
Stemline Therapeutics Inc generated 95.53 % of the combined sales of its peer group, up from 93.34 % a year earlier.
Stemline Therapeutics Inc vs. its Competitors, Q1 2020
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Stemline Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Stemline Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Stemline Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 75.7% for Stemline Therapeutics Inc. Stemline Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Stemline Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Stemline Therapeutics Inc | No | - | - | Yes |
| Competitors combined (1) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
STML Stock Performance relative to its Competitors
STML Stock Performance relative to High-Confidence Competitors
Publicly Traded Peers of Stemline Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Stemline Therapeutics Inc | 563.99 | 47.04 |
| Vbi Vaccines Inc | 1.48 | 9.41 |
| SUBTOTAL | 565.47 | 56.45 |
Sources: Stemline Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Stemline Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Stemline Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicycle Therapeutics Plc | Named by the company | 85% |
| Karyopharm Therapeutics Inc | Named by the company | 85% |
| Vbi Vaccines Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Stemline Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Stemline Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Stemline Therapeutics Inc | 564 | - | - |
| Vbi Vaccines Inc | 1 | 303,581 | -2,709,355 |
| PEERS TOTAL | 1 | 303,581 | -2,709,355 |
Stemline Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vbi Vaccines Inc | US 79.16 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Stemline Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 88.42 % | 64.89 % (avg) | +23.5 pp |
| Operating Margin | -155.51 % | industry median | -6.4 pp |
| EBITDA Margin | -149.99 % | -7.21 % (avg) | -142.8 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.92 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Stemline Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 1.8x | 4.5x | -2.7x |
| Return on Equity | -48.14 % | industry aggregate | -60.37 % |
| Return on Invested Capital | -24.88 % | -2.95 % (avg) | -21.93 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Stemline Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenue Growth | 95.10 % | 59.19 % | - | - | - |
| Operating Margin | -5,752.93 % | -3,734.12 % | - | - | -183.37 % |
| Return on Invested Capital | -18.58 % | -28.02 % | -47.82 % | -64.90 % | -28.83 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Stemline Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Stemline Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Stemline Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Stemline Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Stemline Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Stemline Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 6.4 points below the industry median.
- Return on equity 60.4 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-24.6% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-82.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Stemline Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Stemline Therapeutics Inc | 0.92 | 7.12 | - |
| Vbi Vaccines Inc | 0.36 | 0.56 | 11.45 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Stemline Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Stemline Therapeutics Inc | Q1 2020 | +75.7 % | - |
| Vbi Vaccines Inc | Q1 2024 | +150.3 % | - |
| PEERS TOTAL | +82.3 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Stemline Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Stemline Therapeutics Inc | Q1 2020 | +647.7 % | -80.5 % |
| Vbi Vaccines Inc | Q1 2024 | - | -71.7 % |
Stemline Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Stemline Therapeutics Inc | - | - | - |
| Vbi Vaccines Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Stemline Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Stemline Therapeutics Inc | - | 11.99 |
| Vbi Vaccines Inc | - | 0.16 |
| PEERS AVERAGE | - | 10.02 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.